var data={"title":"Azacitidine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Azacitidine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5688?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=azacitidine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Azacitidine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=azacitidine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Azacitidine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138149\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vidaza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14476760\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vidaza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138170\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimetabolite;</li>\n      <li>\n        Antineoplastic Agent, DNA Methylation Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138150\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Azacitidine is associated with a moderate emetic potential (Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelodysplastic syndromes (MDS):</b> IV, SubQ: Initial cycle: 75 mg/m<sup>2</sup>/day for 7 days. Subsequent cycles: 75 mg/m<sup>2</sup>/day for 7 days every 4 weeks; dose may be increased to 100 mg/m<sup>2</sup>/day if no benefit is observed after 2 cycles and no toxicity other than nausea and vomiting have occurred. Patients should be treated for a minimum of 4 to 6 cycles; treatment may be continued as long as patient continues to benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Alternate (off-label) schedules (which have produced hematologic response) have been used for convenience in community oncology centers (Lyons 2009): SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">75 mg/m<sup>2</sup>/day for 5 days (Mon-Fri), 2 days rest (Sat, Sun), then 75 mg/m<sup>2</sup>/day for 2 days (Mon, Tues); repeat cycle every 28 days <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">50 mg/m<sup>2</sup>/day for 5 days (Mon-Fri), 2 days rest (Sat, Sun), then 50 mg/m<sup>2</sup>/day for 5 days (Mon-Fri); repeat cycle every 28 days <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">75 mg/m<sup>2</sup>/day for 5 days (Mon-Fri), repeat cycle every 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (AML) (off-label use):</b> SubQ: 75 mg/m<sup>2</sup>/day for 7 days every 4 weeks for at least 6 cycles; treatment may be continued as long as patient continues to benefit or until disease progression or unacceptable toxicity (Fenaux 2010). Dose reductions and/or therapy interruption may be required for hematologic toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment based on serum electrolytes:</b> If serum bicarbonate falls to &lt;20 mEq/L (unexplained decrease): Reduce dose by 50% for next treatment course.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138151\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Due to the potential for decreased renal function in the elderly, select dose carefully and closely monitor renal function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138152\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;\">Renal impairment at <i>baseline:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment (CrCl &ge;30 mL/minute): No dosage adjustment necessary (Douvali 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (CrCl &lt;30 mL/minute): No dosage adjustment necessary for cycle 1; azacitidine and its metabolites are excreted renally, monitor closely for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal toxicity <i>during</i> treatment: Unexplained increases in BUN or serum creatinine: Delay next cycle until values reach baseline or normal, then reduce dose by 50% for next treatment course.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4300621\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied). Use is contraindicated in patients with advanced malignant hepatic tumors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4300622\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematologic toxicity: MDS:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">For baseline WBC &ge;3,000/mm<sup>3</sup>, ANC &ge;1,500/mm<sup>3</sup>, and platelets &ge;75,000/mm<sup>3</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nadir count: ANC &lt;500/mm<sup>3</sup> or platelets &lt;25,000/mm<sup>3</sup>: Administer 50% of dose during next treatment course</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nadir count: ANC 500/mm<sup>3</sup> to 1,500/mm<sup>3</sup> or platelets 25,000 to 50,000/mm<sup>3</sup>: Administer 67% of dose during next treatment course</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nadir count: ANC &gt;1,500/mm<sup>3</sup> or platelets &gt;50,000/mm<sup>3</sup>: Administer 100% of dose during next treatment course</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">For baseline WBC &lt;3,000/mm<sup>3</sup>, ANC &lt;1,500/mm<sup>3</sup>, or platelets &lt;75,000/mm<sup>3</sup>: Adjust dose as follows based on nadir counts and bone marrow biopsy cellularity at the time of nadir, unless clear improvement in differentiation at the time of the next cycle:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">WBC or platelet nadir decreased 50% to 75% from baseline and bone marrow biopsy cellularity at time of nadir 30% to 60%: Administer 100% of dose during next treatment course</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">WBC or platelet nadir decreased 50% to 75% from baseline and bone marrow biopsy cellularity at time of nadir 15% to 30%: Administer 50% of dose during next treatment course</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">WBC or platelet nadir decreased 50% to 75% from baseline and bone marrow biopsy cellularity at time of nadir &lt;15%: Administer 33% of dose during next treatment course</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">WBC or platelet nadir decreased &gt;75% from baseline and bone marrow biopsy cellularity at time of nadir 30% to 60%: Administer 75% of dose during next treatment course</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">WBC or platelet nadir decreased &gt;75% from baseline and bone marrow biopsy cellularity at time of nadir 15% to 30%: Administer 50% of dose during next treatment course</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">WBC or platelet nadir decreased &gt;75% from baseline and bone marrow biopsy cellularity at time of nadir &lt;15%: Administer 33% of dose during next treatment course</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> If a nadir defined above occurs, administer the next treatment course 28 days after the start of the preceding course as long as WBC and platelet counts are &gt;25% above the nadir and rising. If a &gt;25% increase above the nadir is not seen by day 28, reassess counts every 7 days. If a 25% increase is not seen by day 42, administer 50% of the scheduled dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138127\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vidaza: 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138114\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138131\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Azacitidine is associated with a moderate emetic potential (Dupuis 2011; Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: The manufacturer recommends equally dividing volumes &gt;4 mL into 2 syringes and injecting into 2 separate sites; however, policies for maximum SubQ administration volume may vary by institution; interpatient variations may also apply. Rotate sites for each injection (thigh, abdomen, or upper arm). Administer subsequent injections at least 1 inch from previous injection sites; do not inject into tender, bruised, red, or hard areas. Allow refrigerated suspensions to come to room temperature (up to 30 minutes) prior to administration. Resuspend by inverting the syringe 2 to 3 times and then rolling the syringe between the palms for 30 seconds.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 10 to 40 minutes; infusion must be completed within 1 hour of (vial) reconstitution.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">If azacitidine suspension comes in contact with the skin, immediately wash with soap and water. If it comes into contact with mucous membranes, flush thoroughly with water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130881\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138130\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Myelodysplastic syndromes:</b> Treatment of myelodysplastic syndromes (MDS) in patients with the following French-American-British (FAB) classification subtypes: Refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475159\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute myeloid leukemia (AML) in patients requiring low-intensity therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401583\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">AzaCITIDine may be confused with azaTHIOprine, decitabine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138120\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Peripheral edema (7% to 19%), chest pain (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Fatigue (13% to 36%), rigors (26%), headache (22%), dizziness (19%), anxiety (5% to 13%), depression (12%), malaise (11%), pain (11%), insomnia (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Erythema (7% to 17%), pallor (16%), skin lesion (15%), skin rash (10% to 14%), pruritus (12%), diaphoresis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Weight loss (&le;16%), pitting edema (15%), hypokalemia (6% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (48% to 71%), vomiting (27% to 54%), constipation (34% to 50%), diarrhea (36%), anorexia (13% to 21%), abdominal pain (11% to 16%), abdominal tenderness (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Thrombocytopenia (66% to 70%; grades 3/4: 58%), anemia (51% to 70%; grades 3/4: 14%), neutropenia (32% to 66%; grades 3/4: 61%), leukopenia (18% to 48%; grades 3/4: 15%), bruise (19% to 31%), petechia (11% to 24%), febrile neutropenia (14% to 16%; grades 3/4: 13%), bone marrow depression (nadir: days 10 to 17; recovery: days 28 to 31)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reactions (14% to 29%): Erythema (35% to 43%; more common with IV administration), pain (19% to 23%; more common with IV administration), bruising (5% to 14%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (29%), arthralgia (22%), limb pain (20%), back pain (19%), myalgia (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough (11% to 30%), dyspnea (5% to 29%), pharyngitis (20%), epistaxis (16%), nasopharyngitis (15%), upper respiratory infection (9% to 13%), pneumonia (11%), rales (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (30% to 52%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">5% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Heart murmur (10%), tachycardia (9%), hypertension (&le;9%), hypotension (7%), syncope (6%), chest wall pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Lethargy (7% to 8%), hypoesthesia (5%), postoperative pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Night sweats (9%), cellulitis (8%), rash at injection site (6%), urticaria (6%), skin nodules (5%), xeroderma (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Gingival hemorrhage (10%), stomatitis (8%), hemorrhoids (7%), dyspepsia (6% to 7%), abdominal distention (6%), loose stools (6%), dysphagia (5%), tongue ulcer (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary tract infection (8% to 9%), dysuria (8%), hematuria (&le;6%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Lymphadenopathy (10%), hematoma (9%), oral mucosal petechiae (8%), postprocedural hemorrhage (6%), oral hemorrhage (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Transfusion reaction (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Herpes simplex infection (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Itching at injection site (7%), hematoma at injection site (6%), induration at injection site (5%), injection site granuloma (5%), skin discoloration at injection site (5%), swelling at injection site (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Muscle cramps (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Rhinorrhea (10%), wheezing (9%), abnormal breath sounds (8%), nasal congestion (6%), pharyngolaryngeal pain (6%), pleural effusion (6%), post nasal drip (6%), rhinitis (6%), rhonchi (6%), atelectasis (5%), sinusitis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Lymphadenopathy (10%), herpes simplex (9%), night sweats (9%), transfusion reaction (7%), mouth hemorrhage (5%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;5%, postmarketing, and/or case reports: Abscess (limb, perirectal), aggravated bone pain, agranulocytosis, anaphylactic shock, atrial fibrillation, azotemia, bacterial infection, blastomycosis, bone marrow failure, cardiac failure, catheter site hemorrhage, cellulitis, cerebral hemorrhage, cholecystectomy, cholecystitis, congestive cardiomyopathy, decreased serum bicarbonate, dehydration, diverticulitis, fibrosis (interstitial and alveolar), gastrointestinal hemorrhage, glycosuria, hemophthalmos, hemoptysis, hepatic coma, hypersensitivity reaction, hypophosphatemia, increased serum creatinine, injection site infection, interstitial pulmonary disease, intracranial hemorrhage, leukemia cutis, melena, necrotizing fasciitis, neutropenic sepsis, orthostatic hypotension, pancytopenia, pneumonitis, polyuria, pulmonary infiltrates, pyoderma gangrenosum, renal failure, renal tubular acidosis, respiratory distress, seizure, sepsis, sepsis syndrome, septic shock, splenomegaly, Sweet's syndrome, tissue necrosis at injection site, toxoplasmosis, tumor lysis syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138134\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to azacitidine, mannitol, or any component of the formulation; advanced malignant hepatic tumors</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138117\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Neutropenia, thrombocytopenia, and anemia are common; may cause therapy delays and/or dosage reductions. Monitor blood counts prior to each cycle (at a minimum), and as clinically indicated. Adjust dose in subsequent cycles based on nadir counts and hematologic response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: May cause hepatotoxicity in patients with preexisting hepatic impairment. Progressive hepatic coma leading to death has been reported in patients with extensive tumor burden due to metastatic disease, especially those with a baseline albumin &lt;30 g/L. Patients with hepatic impairment were excluded from clinical studies for myelodysplastic syndrome (MDS). Use is contraindicated in patients with advanced malignant hepatic tumors. Monitor liver function tests prior to therapy initiation and before each cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Azacitidine is associated with a moderate emetic potential (Dupuis 2011; Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection site reactions: Injection site reactions commonly occurred with subcutaneous administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Renal toxicities, including serum creatinine elevations, renal tubular acidosis (serum bicarbonate decrease to &lt;20 mEq/L associated with alkaline urine and serum potassium &lt;3 mEq/L), and renal failure (some fatal), have been reported with intravenous azacitidine when used in combination with other chemotherapy agents. Monitor serum creatinine and electrolytes prior to therapy initiation and before each cycle. Withhold or reduce the dose with unexplained decreases in serum bicarbonate &lt;20 mEq/L or if elevations in BUN or serum creatinine occur. Patients with renal impairment may be at increased risk for renal toxicity. Monitor closely for toxicity in patients with severe renal impairment (azacitidine and metabolites are excreted renally).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: May cause serious or fatal tumor lysis syndrome (TLS). TLS has occurred in patients despite receiving antihyperuricemic therapy (eg, allopurinol). Assess TLS risk at baseline and monitor for TLS symptoms; treat accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298800\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218155\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8797&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138136\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Based on its mechanism of action, azacitidine may cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised to avoid pregnancy during treatment; verify pregnancy status prior to therapy initiation. In addition, males should be advised to avoid fathering a child while on azacitidine therapy and should use effective contraception during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4300527\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if azacitidine is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138125\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor liver function tests, electrolytes, CBC with differential and platelets, renal function (BUN and serum creatinine) at baseline, prior to each cycle, and more frequently if indicated. Also monitor for hematologic response, nausea/vomiting, and for injection site reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138116\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Antineoplastic effects may be a result of azacitidine's ability to promote hypomethylation of DNA, restoring normal gene differentiation and proliferation. Azacitidine also exerts direct toxicity to abnormal hematopoietic cells in the bone marrow.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138133\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: SubQ: Rapid and complete </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV: 76 &plusmn; 26 L; does not cross blood-brain barrier </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; hydrolysis to several metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: SubQ: ~89% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV, SubQ: ~4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: SubQ: 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (50% to 85%); feces (&lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323005\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (AzaCITIDine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $617.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Vidaza Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $702.29</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6875313\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Vidaza (AR, AT, AU, BB, BE, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IS, JO, JP, KR, LB, LT, LU, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TH, TR, TW, ZA);</li>\n      <li>Xpreza 100 (HK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adams CD, Szumita PM, Baroletti SA, et al, &ldquo;Azacitidine-Induced Interstitial and Alveolar Fibrosis in a Patient With Myelodysplastic Syndrome,&rdquo; <i>Pharmacother</i>, 2006, 25(5):765-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douvali E, Papoutselis M, Spanoudakis E, et al. Safety and efficacy of azacitidine in myelodysplastic syndrome (MDS) patients with mild and moderate renal impairment. <i>Blood</i>. 2012;120(21):1716.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/23726719/pubmed\" target=\"_blank\" id=\"23726719\">23726719</a>]</span><span class=\"doi\">10.1016/j.leukres.2013.05.005</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20026804\"></a>Fenaux P, Mufti GJ, Hellstr&ouml;m-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. <i>J Clin Oncol</i>. 2010;28(4):562-569.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/20026804/pubmed\" target=\"_blank\" id=\"20026804\">20026804</a>]</span><span class=\"doi\">10.1200/JCO.2009.23.8329</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fil&igrave; C, Malagola M, Follo MY, et al. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. <i>Clin Cancer Res</i>. 2013;19(12):3297-3308.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/23596104/pubmed\" target=\"_blank\" id=\"23596104\">23596104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. <i>Haematologica</i>. 2013;98(7):1067-1072.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/23585522/pubmed\" target=\"_blank\" id=\"23585522\">23585522</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kornblith AB, Herndon JE 2nd, Silverman LR, et al, &ldquo;Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study,&rdquo; <i>J Clin Oncol</i>, 2002, 20(10):2441-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/12011121/pubmed\" target=\"_blank\" id=\"12011121\">12011121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyons RM, Cosgriff TM, Modi SS, et al, &ldquo;Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndrome,&rdquo; <i>J Clin Oncol</i>, 2009, 27(11):1850-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/19255328/pubmed\" target=\"_blank\" id=\"19255328\">19255328</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. <i>Cancer</i>. 2012;118(4):1014-1022.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/21761399/pubmed\" target=\"_blank\" id=\"21761399\">21761399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverman LR, Demakos EP, Peterson BL, et al, &ldquo;Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B,&rdquo; <i>J Clin Oncol</i>, 2002, 20(10):2429-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/12011120/pubmed\" target=\"_blank\" id=\"12011120\">12011120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverman LR, Holland JF, Weinberg RS, et al, &ldquo;Effects of Treatment With 5-Azacytidine on the <i>in vivo</i> and <i>in vitro</i> Hematopoiesis in Patients With Myelodysplastic Syndromes,&rdquo; <i>Leukemia</i>, 1993, 7(Suppl 1):21-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/7683352/pubmed\" target=\"_blank\" id=\"7683352\">7683352</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverman LR, McKenzie DR, Peterson BL, et al,&rdquo;Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B,&rdquo; <i>J Clin Oncol</i>, 2006, 24(24):3895-903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/16921040/pubmed\" target=\"_blank\" id=\"16921040\">16921040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sudan N, Rossetti JM, Shadduck RK, et al, &ldquo;Treatment of Acute Myelogenous Leukemia With Outpatient Azacitidine,&rdquo; <i>Cancer</i>, 2006, 107(8):1839-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azacitidine-drug-information/abstract-text/16967444/pubmed\" target=\"_blank\" id=\"16967444\">16967444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vidaza (azacitidine) [prescribing information]. Summit, NJ: Celgene Corporation; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vidaza (azacitidine) [product monograph]. Mississauga, Ontario, Canada: Celgene Inc; October 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8797 Version 159.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F138149\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14476760\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F138170\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F138150\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F138151\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F138152\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F4300621\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F4300622\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F138127\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F138114\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F138131\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130881\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F138130\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475159\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401583\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F138120\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F138134\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F138117\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298800\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218155\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F138136\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4300527\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F138125\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F138116\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F138133\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323005\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6875313\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8797|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=azacitidine-patient-drug-information\" class=\"drug drug_patient\">Azacitidine: Patient drug information</a></li><li><a href=\"topic.htm?path=azacitidine-pediatric-drug-information\" class=\"drug drug_pediatric\">Azacitidine: Pediatric drug information</a></li></ul></div></div>","javascript":null}